ArticleThe EMBO journal2006
Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription.
Article in The EMBO journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A Novel Insight into Paraptosis-Related Classification and Signature in Lower-Grade Gliomas.International journal of genomics · 2022Article
- Targeting the C-Terminal Domain Small Phosphatase 1.Life (Basel, Switzerland) · 2020Review
- Integration of ALV intoOncotarget · 2017Article
- FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21(Cip1/Waf1).The Biochemical journal · 2015Article
- Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.Molecular endocrinology (Baltimore, Md.) · 2014Article
- MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells.The Journal of biological chemistry · 2013Article
- Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.Oncogene · 2012Article
- Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.Oncogene · 2012Article
- The enemy within: intronic miR-26b represses its host gene, ctdsp2, to regulate neurogenesis.Genes & development · 2012Article
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.The EMBO journal · 2011Article
- Differential alterations in gene expression profiles contribute to time-dependent effects of nandrolone to prevent denervation atrophy.BMC genomics · 2010Article
- Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1.The Journal of biological chemistry · 2009Article
- Small C-terminal domain phosphatase enhances snail activity through dephosphorylation.The Journal of biological chemistry · 2009Article
- Structural genomics of protein phosphatases.Journal of structural and functional genomics · 2007Review
- Kinases and protein phosphorylation as regulators of steroid hormone action.Nuclear receptor signaling · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small carboxyl-terminal domain (CTD) phosphatase 2 (SCP2) was identified and verified as a protein that interacts with the androgen receptor (AR). Ectopic expression of SCP2 or two other family members, SCP1 and SCP3, attenuated AR transcriptional activity in LNCaP cells and were recruited in an androgen- and AR-dependent fashion onto the prostate-specific antigen (PSA) promoter. Silencing SCP2 and SCP1 by short hairpin RNAs increased androgen-dependent transcription of the PSA gene and augmented AR loading onto the PSA promoter and enhancer. SCP2 also attenuated glucocorticoid receptor (GR) function, and its silencing increased dexamethasone-mediated PSA mRNA accumulation and GR loading onto the PSA enhancer in LNCaP 1F5 cells. SCP2 silencing was accompanied by augmented recruitment and earlier cycling of RNA polymerase II on the promoter. Ser 5 phosphorylation of the RNA polymerase II CTD, a process necessary for initiation of transcription elongation, occurred significantly earlier in SCP2-silenced than parental LNCaP cells. Collectively, our results suggest that SCP2 is involved in promoter clearance during steroid-activated transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.